Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | PDE9A | O76083 | 10/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | AOC1 | P19801 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275017 | 0.79 | GRM4 (0.51) | PDE9AUTS2R | |
| SCHEMBL20870269 | 0.77 | KDM5A (0.57) | KDM5AKDM5CKDM5BPDE9APARP1 | |
| SCHEMBL22224803 | 0.76 | PDE9A (0.44) | PDE9AUTS2RPARP1 | |
| SCHEMBL22298186 | 0.76 | KDM5A (0.56) | KDM5AKDM5CKDM5BPDE9AKDM4C | |
| SCHEMBL20870599 | 0.75 | KDM5A (0.55) | KDM5AKDM5CKDM5BPDE9ACHUK | |
| SCHEMBL22871658 | 0.73 | KDM5A (0.75) | KDM5AKDM5CKDM5BPDE9ACHUK | |
| SCHEMBL20870607 | 0.73 | KDM5A (0.53) | KDM5AKDM5CKDM5BPDE9ACHUK | |
| SCHEMBL20870616 | 0.73 | KDM5A (0.59) | KDM5AKDM5CKDM5BPDE9APARP1 | |
| SCHEMBL22298103 | 0.70 | KDM5A (0.69) | KDM5AKDM5CKDM5BPDE9ACHUK | |
| SCHEMBL20870262 | 0.70 | KDM5A (1.00) | KDM5AKDM5CKDM5BPDE9ACHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889591-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | KDM5A 1199/4885KDM5C 2394/4885KDM5B 1464/4885 |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | KDM5A 1199/4885KDM5C 2394/4885KDM5B 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.